Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors
Increasing HPV Vaccination Coverage Among Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors: A Multilevel Intervention
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Deanna Teoh, MD, MS
- Phone Number: 612-625-6503
- Email: dkteoh@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Masonic Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Current patient in the University of Minnesota CCSP clinic or the Children's Minnesota Long-Term Follow-up (LTFU) Program clinic.
- Patients seen in the CCSP clinic who do not have a history of cancer but who have received immunosuppressive therapy or HSCT for treatment of a hematologic disorder.
- Survivor of childhood cancer (defined as diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age.
- 6+ months post-treatment; current treatment for graft-versus-host disease allowed
- No previous HPV vaccination or incomplete HPV vaccination (defined as <3 doses post-cancer therapy). Individuals who are unsure of their HPV vaccination status who are unable to find vaccination records per the procedures detailed in Section 5.2, EHR support will be eligible, in concordance with real-world clinical practice regarding HPV vaccination.
Exclusion Criteria:
- Previous completion of the HPV vaccination series. Those who are eligible for re-vaccination per the CDC guidelines will be encouraged by their oncologist to re-vaccinate, but will not be included in the QI study or RCT.
- Unable to read/write in English per self-report (only applies to participants in the RCT [Aim 2]).
- Pregnant at the time of enrollment or plans to become pregnant in the next year. Pregnancy test at the time of enrollment is not required if pregnancy not clinically suspected in concordance with clinical guidelines for HPV vaccine administration.
- Currently receiving treatment for cancer or hematologic disorder or plan for treatment within 12 months of enrollment; treatment for graft-versus-host disease allowed.
- Other contraindications to the HPV vaccine (e.g. history of immediate hypersensitivity reaction to any vaccine component, including yeast).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: GLAm App
Participants will have access to Game based Learning Avatar navigated mobile (GLAm ) app and will receive the receive the quality improvement (QI) intervention plus the GLAm app.
|
Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers.
Users navigate the app using an avatar, and earn points for game components completed.
The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening.
Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
|
|
No Intervention: Usual care
Participants in the control group will not receive the access to the GLAm app.
They will receive the quality improvement (QI) intervention only.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Study enrollment
Time Frame: within 6 months of index clinic visit
|
Number of participants who complete the 3-dose HPV vaccine series within 12 months of study enrollment.
|
within 6 months of index clinic visit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HPV and HPV vaccination knowledge pre- and post-intervention
Time Frame: baseline and 1 year post survivorship clinic visit
|
The change in knowledge is assessed through self reported surveys administered to participants
|
baseline and 1 year post survivorship clinic visit
|
|
Number of participants intent to vaccinate against HPV
Time Frame: At the time of index clinic visit, baseline
|
The number of participants with intent to vaccinate is assessed through self reported surveys administered to participants
|
At the time of index clinic visit, baseline
|
|
Proportion of participants intending to vaccinate initiating and completing the vaccine series
Time Frame: 1 year post index clinic visit
|
The Proportion of participants intending to vaccinate initiating and completing the vaccine series is measured through surveys and health record review
|
1 year post index clinic visit
|
|
Demographics differences associated with vaccination status
Time Frame: 1 year post index clinic visit
|
measure through health record review
|
1 year post index clinic visit
|
|
Cancer occurrences associated with vaccination status
Time Frame: 1 year post index clinic visit
|
measure through health record review
|
1 year post index clinic visit
|
|
Treatment differences associated with vaccination status
Time Frame: 1 year post index clinic visit
|
measure through health record review
|
1 year post index clinic visit
|
|
Number of participants experiencing barriers to vaccination
Time Frame: 1 year post index clinic visit
|
Survey measurement
|
1 year post index clinic visit
|
|
Number of participants using and accepting the game based learning app
Time Frame: 1 year post index clinic visit
|
Survey measurement
|
1 year post index clinic visit
|
|
Concordance between reported and documented vaccination against HPV
Time Frame: 1 year post index clinic visit
|
measured through surveys and health record review
|
1 year post index clinic visit
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Deanna Teoh, MD, MS, Masonic Cancer Center, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021LS099
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.